ArticlePloS one2016
Experimental Phage Therapy for Burkholderia pseudomallei Infection.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Genetic Engineering of Lysogenic-Lytic Switch Genes ImprovesInternational journal of molecular sciences · 2026Article
- Genomic diversity and clade clustering ofiScience · 2026Article
- Phage-mediated control of melioidosis in Southern China: molecular insights and therapeutic potential of N4-like viruses from Hainan.BMC microbiology · 2025Article
- Review
- Review
- Review
- Isolation, characterization, and application of bacteriophage cocktails for the biocontrol of Pseudomonas fluorescens group strains in whole and skimmed milk.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Phage Therapy for Crops: Concepts, Experimental and Bioinformatics Approaches to Direct Its Application.International journal of molecular sciences · 2022Review
- Effective Therapeutic Options for Melioidosis: Antibiotics versus Phage Therapy.Pathogens (Basel, Switzerland) · 2022Review
- A novel lytic phage potentially effective for phage therapy against Burkholderia pseudomallei in the tropics.Infectious diseases of poverty · 2022Article
- Applications of Bacteriophage Cocktails to Reduce Salmonella Contamination in Poultry Farms.Food and environmental virology · 2022Article
- Phage Revolution Against Multidrug-Resistant Clinical Pathogens in Southeast Asia.Frontiers in microbiology · 2022Review
- Rapid Clinical Screening of Burkholderia pseudomallei Colonies by a Bacteriophage Tail Fiber-Based Latex Agglutination Assay.Applied and environmental microbiology · 2021Article
- Bacteriophage infection ofMicrobiology (Reading, England) · 2021Article
- Animal Models of Phage Therapy.Frontiers in microbiology · 2021Review
- Isolation of a Novel Jumbo Bacteriophage Effective AgainstFrontiers in medicine · 2020Article
- Biological challenges of phage therapy and proposed solutions: a literature review.Expert review of anti-infective therapy · 2019Review
- Emerging role of biologics for the treatment of melioidosis and glanders.Expert opinion on biological therapy · 2019Review
- Pharmacologically Aware Phage Therapy: Pharmacodynamic and Pharmacokinetic Obstacles to Phage Antibacterial Action in Animal and Human Bodies.Microbiology and molecular biology reviews : MMBR · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Burkholderia pseudomallei is an intracellular Gram-negative bacterial pathogen intrinsically resistant to a variety of antibiotics. Phages have been developed for use as an alternative treatment therapy, particularly for bacterial infections that do not respond to conventional antibiotics. In this study, we investigated the use of phages to treat cells infected with B. pseudomallei. Phage C34 isolated from seawater was purified and characterised on the basis of its host range and morphology using transmission electron microscopy (TEM). Phage C34 was able to lyse 39.5% of B. pseudomallei clinical strains. Due to the presence of contractile tail, phage C34 is classified as a member of the family Myoviridae, a tailed double-stranded DNA virus. When 2 × 105 A549 cells were exposed to 2 × 107 PFU of phage C34, 24 hours prior to infection with 2 × 106 CFU of B. pseudomallei, it was found that the survivability of the cells increased to 41.6 ± 6.8% as compared to 22.8 ± 6.0% in untreated control. Additionally, application of phage successfully rescued 33.3% of mice infected with B. pseudomallei and significantly reduced the bacterial load in the spleen of the phage-treated mice. These findings indicate that phage can be a potential antimicrobial agent for B. pseudomallei infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.